Centiva Capital, LP Mirati Therapeutics, Inc. Transaction History

Centiva Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $49,087 - $71,527	-825 Reduced 80.49%	200 $14,000
Q2 2022 Aug 17, 2022	SELL	$39.16 - $88.71 $293,700 - $665,325	-7,500 Reduced 87.98%	1,025 $69,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $333,839 - $756,252	8,525 New	8,525 $573,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $141,382 - $203,800	-1,071 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $481,613 - $646,805	-3,645 Reduced 77.29%	1,071 $189,000

Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $92,304 - $115,206	-641 Reduced 11.97%	4,716 $762,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $167,024 - $232,912	1,051 Added 24.41%	5,357 $918,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $429,270 - $636,475	2,649 Added 159.87%	4,306 $946,000
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $611,830 - $903,592	-5,402 Reduced 76.53%	1,657 $275,000
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $508,318 - $849,833	7,059 New	7,059 $806,000

3.52M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.